Ketalar labelling in Canada now includes hepatobiliary toxicity risk.

The Canadian Product Monograph (CPM) for Ketalar (ketamine hydrochloride) now includes new safety information regarding the risk of hepatobiliary toxicity linked with its use, says Health Canada. The agency recommended that regular liver function monitoring is undertaken with repeated use of ketamine, and that ketamine should be discontinued in patients who experience clinically significant elevations in liver enzymes. [Extracted from the article]

Copyright of Reactions Weekly is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)